Hansa Biopharma AB Asset Resilience Ratio

Latest as of June 2023: 0.00%

Hansa Biopharma AB asset resilience ratio. Hansa Biopharma AB (HNSA) has an Asset Resilience Ratio of 0.00% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Hansa Biopharma AB defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

Skr0.00

≈ $0.00 USD Cash + Short-term Investments

Total Assets

Skr1.36 Billion

≈ $146.63 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of Hansa Biopharma AB (2012–2022)

Asset resilience ratio of Hansa Biopharma AB from 2012 to 2022. This chart shows how Hansa Biopharma AB's Asset Resilience Ratio has changed over time. Read Hansa Biopharma AB debt and liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Hansa Biopharma AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Hansa Biopharma AB total assets.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr0.00	0%
Short-term Investments	Skr0.00	0%
Total Liquid Assets	Skr0.00	0.00%

Asset Resilience Insights

Limited Liquidity: Hansa Biopharma AB maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company maintains a balanced mix of cash and short-term investments.

Hansa Biopharma AB Industry Peers by Asset Resilience Ratio

Compare Hansa Biopharma AB's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Bavarian Nordic CO:BAVA	Biotechnology	10.83%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Hansa Biopharma AB Asset Resilience Ratio by Year (2012–2022)

Hansa Biopharma AB asset resilience ratio by year from 2012 to 2022. The table below shows the annual Asset Resilience Ratio data for Hansa Biopharma AB.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	0.00%	Skr0.00 ≈ $0.00	Skr1.69 Billion ≈ $181.59 Million	--
2021-12-31	23.46%	Skr237.62 Million ≈ $25.57 Million	Skr1.01 Billion ≈ $108.99 Million	+6.86pp
2020-12-31	16.60%	Skr238.14 Million ≈ $25.63 Million	Skr1.43 Billion ≈ $154.37 Million	-46.54pp
2019-12-31	63.14%	Skr419.40 Million ≈ $45.13 Million	Skr664.24 Million ≈ $71.48 Million	+18.82pp
2018-12-31	44.32%	Skr418.75 Million ≈ $45.06 Million	Skr944.82 Million ≈ $101.68 Million	+39.18pp
2017-12-31	5.14%	Skr34.98 Million ≈ $3.76 Million	Skr680.41 Million ≈ $73.22 Million	-7.73pp
2016-12-31	12.87%	Skr39.99 Million ≈ $4.30 Million	Skr310.67 Million ≈ $33.43 Million	+12.87pp
2014-12-31	0.00%	Skr1.00 ≈ $0.11	Skr54.31 Million ≈ $5.84 Million	+4.07pp
2013-12-31	-4.07%	Skr-2.06 Million ≈ $-222.17K	Skr50.78 Million ≈ $5.46 Million	-4.46pp
2012-12-31	0.40%	Skr261.61K ≈ $28.15K	Skr65.80 Million ≈ $7.08 Million	--

pp = percentage points

About Hansa Biopharma AB

ST:HNSA Sweden Biotechnology

Market Cap

$426.49 Million

Skr3.96 Billion SEK

Market Cap Rank

#12773 Global

#212 in Sweden

Share Price

Skr39.74

Change (1 day)

+2.90%

52-Week Range

Skr24.88 - Skr46.68

All Time High

Skr348.00